38446-95-6 Usage
General Description
Tert-butyl 4-oxocyclohexanecarboxylate is a chemical compound with the molecular formula C11H18O3. It is a derivative of cyclohexanecarboxylic acid and is commonly used in the synthesis of pharmaceuticals and agrochemicals. This chemical is also used as a solvent in various industrial applications. Tert-butyl 4-oxocyclohexanecarboxylate is a clear, colorless liquid with a fruity odor, and it is stable under normal conditions of use and storage. It is important to handle this chemical with care and follow proper safety protocols, as it can be harmful if ingested, inhaled, or comes into contact with the skin or eyes.
Check Digit Verification of cas no
The CAS Registry Mumber 38446-95-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,4,4 and 6 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 38446-95:
(7*3)+(6*8)+(5*4)+(4*4)+(3*6)+(2*9)+(1*5)=146
146 % 10 = 6
So 38446-95-6 is a valid CAS Registry Number.
InChI:InChI=1/C11H18O3/c1-11(2,3)14-10(13)8-4-6-9(12)7-5-8/h8H,4-7H2,1-3H3
38446-95-6Relevant articles and documents
DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
-
Page/Page column 39; 51-52, (2020/01/24)
The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS
-
, (2017/02/24)
The present invention relates to compounds characterized by having a structure according to the following Formula I, or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
-
Page/Page column 150, (2014/10/03)
Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
